A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease

Article Abstract:

The combination of ribavirin and ddI appears to be effective in treating HIV infection. Ribavirin enhances the activation of ddI in the body, thus augmenting its effectiveness. Researchers evaluated the drug combination in 19 patients, who received ddI alone for 4 weeks and then in combination with ribavirin for the remainder of the 12-week study. Only 22% experienced a reaction to the drugs. The drug combination reduced the levels of virus in the blood and also raised CD4 T cell counts. However, in 53% of the patients, the virus developed a gene mutation that would allow it to resist the drugs.

Ribavirin

---

Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects

Article Abstract:

The drug ganciclovir may interact with other AIDS drugs. Ganciclovir is used to treat cytomegalovirus infections, which are common in AIDS patients. Researchers studied the interaction of ganciclovir with zidovudine (AZT), didanosine (ddI) and probenecid in 26 HIV patients with cytomegalovirus infection. Ganciclovir affected the metabolism of most of the drugs, especially when given at certain times. This could cause greater toxicity on the part of some drugs such as ddI. HIV patients on AIDS drugs who are given ganciclovir should be closely monitored.

Analysis, Physiological aspects, Ganciclovir, Drug interactions, Pharmacokinetics, Probenecid

---

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)

Article Abstract:

The authors compared the three-drug combination of delavirdine mesylate plus zidovudine and didanosine to two drug combinations of the same drugs. The three-drug combination was safe and superior in varying degrees, from small to significant, to the two-drug combinations.

Testing, Drug therapy, Combination, Combination drug therapy

Similar abstracts:

• Abstracts: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus
• Abstracts: A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population
• Abstracts: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
• Abstracts: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
• Abstracts: Osteoarthrosis of the hip in women and its relation to physical load at work and in the home. Osteoarthritis of the knee and physical load from occupation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.